Gauri Godbole, from Public Health England, gives us an overview of recent advances and updates in the field of gastrointestinal infections – from the impact of the microbiome to the growing threat of antimicrobial resistance.
Browsing: Clinical > Antimicrobial Resistance
A Phase II trial has demonstrated that a new investigational antibiotic, cefiderocol, is as effective as the current standard-of-care for treating complicated UTIs caused by multi-drug resistant bacteria.
The UK’s Health & Social Care Select Committee has concluded that antimicrobial resistance should be established as a ‘top five policy priority’ for the UK Government.
In this interview we speak to Amy Mathers about her research on the role of hospital plumbing in the evolution and exchange of genes of drug resistance.
Scientists, led by the National University of Singapore and the University of Glasgow, have used the term ‘lateral transduction’ to describe a novel, dangerously-potent mechanism of bacteriophage-induced genetic transduction.
In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
Nearly half of prescriptions for antibiotics were written without an infection-related diagnosis, according to a study of 509,534 prescriptions reported at IDWeek today.
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
GARDP and Novartis have announced a partnership hoping to accelerate the development and availability of generic antibiotics for children in LMICs.